GCVI Summit 2018
Skip Content

11 October 2017

Allena leans into $92m IPO

Allena Pharmaceuticals, a Pharmstandard-backed developer of metabolic and kidney disorder treatments, has filed to go public after raising $93m in venture capital.

Author: Robert Lavine, News Editor

Allena Pharmaceuticals, a US-based developer of treatments for metabolic and kidney disorders, has filed to raise up to $92m in an initial public offering that will allow pharmaceutical company Pharmstandard to exit.